Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients

Bone Marrow Transplantation

Volumn 38, Issue 1, 2006, Pages 29-35

  Choi, J S ^a,b   Lee, S H ^b   Chung, S J ^c   Yoo, K H ^d   Sung, K W ^d   Koo, H H ^d  

^a Samsung Medical Center   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c Seoul National University   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cyclosporin A; Hematopoietic stem cell transplantation; Pediatric; Pharmacokinetic

Indexed keywords

CIPOL; CYCLOSPORIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; APLASTIC ANEMIA; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INFORMED CONSENT; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALE; PEDIATRICS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; ANEMIA, APLASTIC; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA; MALE; METABOLIC CLEARANCE RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745226430     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705402     Document Type: Article

References (43)

1. Atkinson K. Cyclosporin in bone marrow transplantation. Bone Marrow Transplant 1987; 1: 265-270.
2. Storb R, Deeg HJ, Pepe M, Frederick A, Anasetti C, Beatty P et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
3. Yau JC, LeMaistre CF, Zagars GK, William LA, Meneghetti CM, Luke DR et al. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 1990; 5: 269-272.
4. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225-1230.
5. Simpson D. Drug therapy for acute graft-versus-host disease prophylaxis. J Hematother Stem Cell Res 2000; 9: 317-325.
6. Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev 2000; 14: 190-204.
7. Locatelli F, Uderzo C, Dini G, Zecca M, Arcese W, Messina C et al. Graft-versus-host disease in children: The AIEOP-BMT group experience with cyclosporin A. Bone Marrow Transplant 1993; 12: 627-633.
8. Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405-411.
9. Shaw LM, Bowers L, Demers L, Freeman D, Moyer T, Sanghvi A et al. Critical issues in cyclosporine monitoring: Report of the task force on cyclosporine monitoring. Clin Chem 1987; 33: 1269-1288.
10. Lindholm A, Henricsson S, Lind LM, Dahlqvist R. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol 1988; 34: 461-464.
11. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472-495.
12. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monitor 1991; 13: 465-477.
13. Atkinson K, Biggs JC, Britton K, Short R, Mrongovius R, Concannon A et al. Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: Implications of clinical gut dysfunction. Br J Hematol 1984; 56: 223-231.
14. Yee GC. Pharmacokinetic and pharmacodynamic studies of cyclosporine in bone marrow transplantation. Transplant Proc 1990; 22: 1327-1330.
15. Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ et al. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transplant 2000; 26: 545-551.
16. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ. Age-dependent cyclosporine: Pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986; 40: 438-443.
17. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet 1997; 32: 481-495.
18. Burckart G, Starzl T, Williams L, Sanghvi A, Gartner C, Venkataramanan JR et al. Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant patients. Transplant Proc 1985; 17: 1172-1175.
19. Burckart GJ, Venkataramanan R, Ptachcinski RJ, Ptachcinski RJ, Starzl TE, Gartner JC et al. Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol 1986; 26: 647-651.
20. Dunn SP, Cooney GF, Kulinsky A, Falkenstein K, Pierson A, Elder CA et al. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. Transplantation 1995; 60: 1438-1442.
21. Neiberger R, Weiss R, Gomez M, Greifer I, Tellis VA, Matas AJ. Elimination kinetics of cyclosporine following oral administration to children with renal transplants. Transplant Proc 1987; 19: 1525.
22. Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL. Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol 1991; 5: 1-4.
23. Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AL. Small bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990; 322: 733-738.
24. Mochon M, Cooney G, Lum B, Caputo C, Dunn S, Goldsmith B et al. Pharmacokinetics of cyclosporine after renal transplant in children. J Clin Pharmacol 1996; 36: 580-586.
25. Cooney GF, Dunn SP, Kaiser B, Kulinsky AV, Mochon M, Heifets M. Oral cyclosporine pharmacokinetics in pediatric renal and liver transplant recipients. Transplant Proc 1994; 26: 2779-2780.
26. Dunn S. Neoral use in the pediatric transplant recipient. Transplant Proc 2000; 32 (Suppl 3A): 20-26.
27. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®) in organ transplantation. Drugs 2001; 61: 1957-2016.
28. Caudell KA, Adams J. Cyclosporine administration practices on bone marrow transplant units: A national survey. Oncol Nurs Forum 1990; 17: 563-568.
29. Miller KB, Schenkein DP, Comenzo R, Erban JK, Fogaren T, Hirsch CA et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1994; 68: 15-20.
30. Witte T, Hoitsma A, Manoiu MM, Janssen J. Monitoring of cyclosporin during continuous intravenous administration. Bone Marrow Transplant 1986; 1: 147-150.
31. Kagawa Y, Sawada J, Yamada S, Matsuda H, Kageyama S, Masuya M et al. Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone marrow transplanted recipients who received the continuous intravenous infusion. Biol Pharm Bull 2003; 26: 1115-1119.
32. Lindholm A. Therapeutic monitoring of cyclosporin - an update. Eur J Clin Pharmacol 1991; 41: 273-283.
33. Morris RG, Ilett KF, Tett SE, Ray JE, Fullinfaw RO, Cooke R et al. Cyclosporin monitoring in Australasia: 2002 update of consensus guidelines. Ther Drug Monitor 2002; 24: 677-688.
34. Kari T. A review of assay methods for cyclosporin. Clin Phatmacokinet 1992; 23: 173-190.
35. Holt DW, Johnson A. Cyclosporin A: Analytic methodology and factors affecting therapeutic drug monitoring. Ther Drug Monitor 1995; 17: 625-630.
36. Nashan B, Bleck J, Wonigeit K, Vogt P, Christians U, Sewing KF et al. Effect of the application form of cyclosporine on blood levels: comparison of oral solution and capsules. Transplant Proc 1988; 20: 637-639.
37. Hilbrands LB, Hoitsma AJ, van den Berg JWO, Koene RAP. Cyclosporin A blood levels during use of cyclosporin as oral solution or in capsules: comparison of pharmacokinetic parameters. Transplant Int 1991; 4: 125-127.
38. Eadon H, Rose M, O'Neill R, Leaver N, Yacoub M. A pharmacokinetic comparison of cyclosporin oral solution and cyclosporin capsules in heart and lung transplant recipients. Transpl Int 1995; 8: 35-40.
39. Papachristou F, Gakis D, Sotiriou I, Liatsis I, Takoudas D, Antoniadis A. Pharmacokinetic study of twice vs thrice daily dosing of Sandimmun Neoral in pediatric renal transplant patients. Transplant Proc 1998; 30: 1988-1990.
40. Portman RJ, Meier-Kriesche HU, Swinford R, Brannan P, Kahan BD. Reduced variability of Neoral pharmacokinetic studies in pediatric renal transplantation. Pediatr Nephrol 2000; 15: 2-6.
41. Blifeld C, Ettenger RB. Measurement of cyclosporine levels in samples obtained from peripheral sites and indwelling lines. NEJM 1987; 317: 509.
42. Carreras E, Lozano M, Deulofeu R, Roman S, Granena A, Rozman C. Influence of different indwelling lines on the measurement of blood cyclosporin A levels. Bone Marrow Transplant 1988; 3: 637-639.
43. Busca A, Miniero R, Vassallo E, Leone L, Oddenino O, Madon E. Monitoring of cyclosporine blood levels from central venous lines: A misleading assay? Ther Drug Monitor 1994; 16: 71-74.